Horizon Pharma (HZNP) PT Raised to $35 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Horizon Pharma (NASDAQ: HZNP) to $35.00 (from $33.00) while maintaining an Outperform rating.

The analyst commented, "Q2 was nicely above, with strong performance in the orphan portfolio, driven by the critical growth asset Krystexxa. With Krystexxa's +35% Y/Y performance, management is now targeting 20%+ growth in 2019, and correspondingly, management increased full year guidance to reflect this strength. With tepro set to provide meaningful P&L leverage & duration, the growth story is poised to accelerate. Add."

You May Also Be Interested In

• Deutsche Bank Upgrades Sirius XM Radio (SIRI) to Buy, 'mispriced based on a large disconnect between consensus estimates and what we believe the company can achieve
• MiniMed Group (MMED) PT Raised to $28 at UBS
• Komatsu (6301:JP) (KMTUY) PT Raised to JPY7,600 at Nomura/Instinet